Details for Patent: 10,023,560
✉ Email this page to a colleague
Which drugs does patent 10,023,560 protect, and when does it expire?
Patent 10,023,560 protects QUVIVIQ and is included in one NDA.
This patent has thirty-seven patent family members in thirty-two countries.
Summary for Patent: 10,023,560
| Title: | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-meth- oxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
| Abstract: | The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist. |
| Inventor(s): | Boss; Christoph (Allschwil, CH), Brotschi; Christine (Allschwil, CH), Gude; Markus (Allschwil, CH), Heidmann; Bibia (Allschwil, CH), Sifferlen; Thierry (Allschwil, CH), Von Raumer; Markus (Allschwil, CH), Williams; Jodi T. (Allschwil, CH) |
| Assignee: | IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) |
| Application Number: | 15/702,281 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,023,560
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF INSOMNIA | ⤷ Try a Trial | ||||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF INSOMNIA | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,023,560
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/IB2013/060595 | Dec 3, 2013 | |
International Family Members for US Patent 10,023,560
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014358743 | ⤷ Try a Trial | |||
| Brazil | 112016012625 | ⤷ Try a Trial | |||
| Canada | 2929720 | ⤷ Try a Trial | |||
| Chile | 2016001348 | ⤷ Try a Trial | |||
| China | 105793258 | ⤷ Try a Trial | |||
| Cyprus | 1119687 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
